Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
$12.13
$0.52(2.83%)
At close: 4:00 PM EST
$12.13
$0.52(2.83%)
Day’s Range― - ―
52-Week Range$4.72 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)3.47M
Market Cap
$1.57B
Enterprise Value$1.24B
Total Cash (Recent Filing)$164.12M
Total Debt (Recent Filing)$410.31M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Feb 25, 2026EPS Estimate
0.04Last Dividend Ex-Date
Dec 17, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding129,387,800
10 Day Avg. Volume2,177,032
30 Day Avg. Volume3,465,719
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)0.46
Price to Sales (P/S)0.63
P/FCF Ratio-12.26
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-30.79
Forecast
1Y Price Target
$13.29Price Target Upside9.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.09
Revenue Forecast (FY)$725.44M
Bulls Say, Bears Say
Bulls Say
EarningsNeoGenomics reported better than expected 3Q revenue of $187.8 million, up 11.9%.
Legal DevelopmentRaDaR recently secured a favorable court ruling against Natera, effectively removing a key legal overhang and paving the way for clinical launch.
Product LaunchNeoGenomics plans to launch RaDaR ST MRD test into the clinical oncology channel during 1Q 2026 for which it has already received MolDX reimbursement approval.
Bears Say
Management CredibilityManagement needs to reestablish its credibility before any upward revision beyond the consensus is warranted.
Market CompetitionQuestions remain on the sustainability of growth rate and competitive position in the liquid biopsy/NGS market.
Non-clinical RevenueRevenue from Non-clinical sources continues to languish due to the discontinuation of RaDaR 1.0 and macro pressure on the biopharma testing market.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $4.72 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.57B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Feb 25, 2026 which is in 89 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Oct 28, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.009.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.04.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 129,387,800 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.03 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.29 (9.56% Upside)
$13.29 (9.56% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.39%
12-Months-Change
Fundamentals
Return on Equity
-12.99%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing services, specializing in advanced diagnostic services and information to support cancer treatment decisions. The company operates in the healthcare sector, primarily focusing on oncology, and offers a wide range of products and services, including molecular testing, cytogenetics, and pathology services. NeoGenomics' core mission is to improve patient outcomes through innovative diagnostic solutions that help oncologists and other healthcare providers understand the genetic makeup of cancer, facilitating personalized treatment options for patients.
NEO Company Deck
NEO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance in the clinical segment, driven by volume and revenue growth, successful acquisitions, and favorable legal outcomes. However, challenges remain in nonclinical revenue, particularly in pharma, which are expected to persist into 2026.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$13.29
▲(9.56% Upside)
Technical Analysis
Ownership Overview
1.22% Insiders
29.23% Mutual Funds
30.99% Other Institutional Investors
14.30% Public Companies and
Individual Investors